ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Daniel Celemín
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pascual, J.
Right arrow Articles by Ortuño, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pascual, J.
Right arrow Articles by Ortuño, J.
Related Collections
Right arrow Valve disease
Right arrow Chest wall

Ann Thorac Surg 2007;84:271-272
© 2007 The Society of Thoracic Surgeons

Case Reports

Uneventful Thoracic Healing With Everolimus After Aortic Valve Replacement

Julio Pascual, MDa,*, Cristina Galeano, MDa, Daniel Celemín, MDb, Maria C. Alarcón, MDa, Roberto Marcén, MDa, Ana M. Fernández, MDa, Francisco J. Burgos, MDc, Joaquin Ortuño, MDa

a Department of Nephrology, Hospital Ramón y Cajal, Madrid, Spain
b Department of Cardiac Surgery, Hospital Ramón y Cajal, Madrid, Spain
c Department of Urology, Hospital Ramón y Cajal, Madrid, Spain

Accepted for publication February 20, 2007.

* Address correspondence to Dr Pascual, Department of Nephrology, Hospital Ramón y Cajal, Carretera de Colmenar km 9,100, Madrid, 28034, Spain (Email: julpascual{at}gmail.com).

Impaired wound healing problems constitute a frequent severe adverse event associated to de novo use of proliferation signal inhibitors sirolimus or everolimus in kidney, heart, and lung transplantation. No published experience on the best practice to manage these drugs in patients scheduled for elective thoracic surgery is available. Herein we present a renal allograft recipient with recurrent cutaneous neoplasia who was maintained on everolimus plus prednisone undergoing aortic valve replacement. Although the most advisable practice may be everolimus withdrawal during the perioperative period, everolimus was maintained with transient dose decrease without any wound healing problem.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2007 by The Society of Thoracic Surgeons.